Shelton Capital Management’s Corcept Therapeutics CORT Stock Holding History

Shelton Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$226K	Buy	+2,604	New	+$157K	﹤0.01%	652
2025 Q4	–	Sell	-3,379	Closed	-$281K	–	724
2025 Q3	$281K	Hold	3,379	–	–	0.01%	531
2025 Q2	$248K	Sell	3,379 -125,365	-97%	-$9.09M	0.01%	571
2025 Q1	$14.7M	Sell	128,744 -170	-0.1%	-$10.3K	0.35%	69
2024 Q4	$6.5M	Sell	128,914 -10,867	-8%	-$569K	0.16%	136
2024 Q3	$6.47M	Sell	139,781 -713	-0.5%	-$25.3K	0.17%	125
2024 Q2	$4.56M	Buy	+140,494	New	+$3.85M	0.12%	161
2019 Q4	–	Sell	-10,698	Closed	-$151K	–	841
2019 Q3	$151K	Hold	10,698	–	–	0.01%	778
2019 Q2	$119K	Buy	10,698 +10,572	+8,390%	+$118K	0.01%	805
2019 Q1	$10.7K	Sell	126 -10,572	-99%	-$131K	0.04%	380
2018 Q4	$143K	Buy	+10,698	New	+$141K	0.01%	737

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Shelton Capital Management's CORT Position: Q2 2026 in Review

Shelton Capital Management opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 2,604 shares worth $226K. The stake represents ﹤0.01% of the portfolio and ranks #652 among its holdings. This is a return to the name: Shelton Capital Management previously reported a position in CORT as recently as Q3 2025.

Shelton Capital Management first reported a position in CORT in Q4 2018 and has held it in 11 quarters since. The position peaked at $14.7M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Shelton Capital Management held 2,604 shares of Corcept Therapeutics worth $226K as of Q2 2026.
Corcept Therapeutics was a new Shelton Capital Management position in Q2 2026.
Corcept Therapeutics made up ﹤0.01% of Shelton Capital Management's portfolio in Q2 2026, its #652 holding.
Shelton Capital Management first reported a position in Corcept Therapeutics in Q4 2018 and has held it in 11 quarters since.
Shelton Capital Management's Corcept Therapeutics position peaked at $14.7M in Q1 2025.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Shelton Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.